AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$LUNG

Radhakrishnan Srikanth sold $32K of LUNG

Radhakrishnan Srikanth (Chief Science & Techn. Officer) sold 14,245 shares of Pulmonx Corp (LUNG) at $2.26 across 4 trades on 2026-09-01.

Original reporting
SEC EDGAR · Radhakrishnan Srikanth
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LUNG
Bearish
medium confidence
Mentioned
$LUNG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGBearishLow
01

Why it matters

The disclosed sale is modest relative to total holdings and unlikely to affect market perception significantly.

02

Market read

Primary insider sale filing; low materiality but provides fresh data for compliance and monitoring.

03

What to watch

Insider retains a large stake (over 300k shares) indicating continued confidence.

Relevance 3/10Novelty 5/10Timing: filed today (2026-09-03)

Background

Pulmonx Corp (LUNG) is a US-listed biotech focused on pulmonary therapies. Insider transactions are disclosed via Form 4.

Company-level read

Ticker impact

$LUNGBearishMedium confidence
Context

SEC Form 4 disclosed that Chief Science & Techn. Officer Radhakrishnan Srikanth sold 14,245 shares of Pulmonx Corp for $32,193.70 on 2026-09-01.

Expected impact

slight short-term downward pressure

Evidence & confidence

Sale size is under $50k and represents a minor portion of insider holdings; market impact is limited.

Market effects

Sector

Minimal effect on the biotech sector; insider sales are routine.

Regional

No regional impact.

Global

Limited to investors tracking Pulmonx.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Officer
    Radhakrishnan Srikanth

    Chief Science & Techn. Officer of Pulmonx Corp

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LUNG insider trading history →

Related articles

JUL 31
$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

rttnews.com6 min
JUL 29
$LUNGMed

Pulmonx Corp (LUNG): Results of Operations and Financial Condition

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the secon

SEC EDGAR 8-K3 min